Initial Treatment for RA-ILD While Awaiting Rheumatology
Start mycophenolate as first-line therapy for RA-ILD, as it is the preferred immunosuppressive agent across all systemic autoimmune rheumatic disease-associated ILD according to the 2023 ACR/CHEST guidelines 11.
Treatment Algorithm
First-Line Therapy Options (in order of preference):
Preferred:
Additional Options (if mycophenolate contraindicated/not tolerated):
Glucocorticoid Use:
Short-term glucocorticoids (≤3 months) may be used cautiously as bridging therapy while initiating immunosuppression, but avoid long-term daily glucocorticoids 11. The guidelines strongly recommend against chronic glucocorticoid monotherapy for RA-ILD.
Critical Considerations Before Starting Treatment
Assess Disease Severity:
If rapidly progressive ILD (RP-ILD):
- Immediate IV methylprednisolone pulse therapy 11
- Add 1-2 additional agents upfront: rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitor, or JAK inhibitor 11
- Consider early lung transplant referral 1
If stable/slowly progressive ILD:
Medication Safety Review:
STOP these medications if currently prescribed:
- Methotrexate (associated with pulmonary toxicity, though recent data shows it may reduce mortality when tolerated) 23
- Leflunomide (conditionally recommended against in RP-ILD) 1
Exercise caution with:
- TNF inhibitors (conflicting evidence; some suggest worsening ILD) 4
- Abatacept (may be considered for second-line, but not first-line for ILD) 5
Practical Dosing
Mycophenolate:
- Start 1000-1500 mg twice daily (or mycophenolic acid equivalent)
- Titrate based on tolerance and GI side effects
If using short-term glucocorticoids:
- Prednisone 0.5-1 mg/kg/day initially, taper over 3 months
- Avoid doses >15 mg/day long-term due to infection risk and lack of efficacy data
Common Pitfalls to Avoid
Do NOT use methotrexate, leflunomide, or TNF inhibitors as first-line therapy - these are conditionally recommended against for RP-ILD and have unclear safety profiles in stable RA-ILD 11
Do NOT delay treatment - Real-world data shows ACR/CHEST guideline-recommended therapies are underutilized (only 1.2-12% of patients receive them), leading to worse outcomes 2
Do NOT use nintedanib or pirfenidone as monotherapy initially - These antifibrotics are reserved for progressive disease despite immunosuppression or as add-on therapy 11
Do NOT continue chronic high-dose glucocorticoids alone - Associated with increased infection risk without clear ILD benefit 11
Monitoring Plan Until Rheumatology Appointment
- Baseline pulmonary function tests (FVC, DLCO)
- Baseline high-resolution CT chest if not already done
- Monitor for infection (most common serious adverse event with immunosuppression)
- CBC, CMP, LFTs at 2-4 weeks after starting mycophenolate
- Assess for GI intolerance (most common reason for mycophenolate discontinuation)
When to Escalate Urgently
Refer immediately to pulmonology/rheumatology if:
- Rapidly declining FVC (>10% decline over 6 months)
- New/worsening dyspnea at rest
- New oxygen requirement
- Radiographic progression on imaging
The 2023 ACR/CHEST guidelines represent the most comprehensive and recent evidence-based approach to RA-ILD management 1111, supported by the 2026 ERS/EULAR guidelines which similarly recommend immunosuppressive treatment for RA-ILD 6. Recent network meta-analyses confirm that rituximab, tocilizumab, and methotrexate (when tolerated) are associated with lower mortality, while JAK inhibitors show favorable tolerability profiles 3.